2024 Latin America Conference on Lung Cancer (LALCA) - Posters-PP01.12: Tyrosine Kinase Inhibitors (Alone or in Combination) for the Management of Advanced Thymic Epithelial Tumors (TETs) Among Hispanics

PP01.12: Tyrosine Kinase Inhibitors (Alone or in Combination) for the Management of Advanced Thymic Epithelial Tumors (TETs) Among Hispanics

Back to course

Pdf Summary

This study focuses on the management of advanced thymic epithelial tumors (TETs) using tyrosine kinase inhibitors (TKIs) among Hispanic patients. TETs are rare malignancies with limited treatment options beyond initial chemotherapy. Conducted across several Latin American oncology centers, the study aimed to evaluate the efficacy of TKIs and identify prognostic factors for advanced TET treatment.<br /><br />The retrospective analysis included 34 patients with confirmed thymic carcinoma, predominantly at advanced stages (IVA and IVB). The median age was 52, with 35% female representation. Many patients exhibited symptoms at diagnosis, and a notable proportion had a family history of cancer. Molecular profiling revealed that the TP53 gene was commonly mutated, with other alterations found in genes like PIK3CA, KIT, and CNV in CCND2, among others.<br /><br />Treatment regimens involved Lenvatinib, sunitinib, a combination of Lenvatinib/Pembrolizumab, and everolimus, administered mainly as second-line treatments. Lenvatinib was the most commonly used, followed by sunitinib. The overall response rate to TKIs was 15%, with partial responses observed in 5 patients. TKI treatment resulted in disease stabilization in 56% of participants. Progression-free survival (PFS) showed a median of 5.88 months, while the median overall survival (OS) from TET diagnosis was 53.7 months. Earlier treatment lines correlated with better PFS outcomes.<br /><br />The study concluded that TKIs are viable treatment options for advanced TETs in Hispanic patients, particularly as second-line therapies. The findings underscore the potential of TKIs to improve outcomes in a demographic with limited treatment avenues, emphasizing their role as a valuable strategy in TET management.

Asset Subtitle

Jairo Andrés Zuluaga León

Keywords

advanced thymic epithelial tumors

tyrosine kinase inhibitors

Hispanic patients

Lenvatinib

sunitinib

thymic carcinoma

molecular profiling

TP53 mutation

progression-free survival

second-line therapies